Announcements
- JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
- Idorsia publishes an invitation to a bondholder meeting
- Idorsia publishes a Financial Status required for an upcoming bondholder meeting
- Idorsia takes steps to address short-term liquidity needs
- Idorsia thanks Guy Braunstein for his years of service as he retires
- US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration
- Idorsia and Viatris enter into a significant global research and development collaboration
- Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
- New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
More ▼
Key statistics
As of last trade, Idorsia Ltd (19T:BRN) traded at 1.79, 35.96% above the 52 week low of 1.32 set on Jan 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.85 |
---|---|
High | 1.85 |
Low | 1.79 |
Bid | 1.76 |
Offer | 1.78 |
Previous close | 2.01 |
Average volume | 15.56k |
---|---|
Shares outstanding | 188.84m |
Free float | 120.56m |
P/E (TTM) | -- |
Market cap | 328.97m CHF |
EPS (TTM) | -2.11 CHF |
Data delayed at least 15 minutes, as of Apr 25 2024.
More ▼